Similar articles for PMID: 10357371

Year	Number of Results
1990	1
1993	1
1994	1
1995	1
1996	7
1997	20
1998	41
1999	50
2000	75
2001	44
2002	37
2003	27
2004	12
2005	8
2006	9
2007	5
2008	2
2009	1
2010	6
2011	3
2012	2
2013	3
2015	1
2017	1
2018	1
2019	1
2020	1
2021	1
2022	1
2024	0

1

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC. Cohen Stuart JW, et al. AIDS. 1999 May 7;13(7):F53-8. doi: 10.1097/00002030-199905070-00001. AIDS. 1999. PMID: 10357371 Clinical Trial.

2

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM. Mitsuyasu RT, et al. AIDS. 1998 Jul 30;12(11):F103-9. doi: 10.1097/00002030-199811000-00001. AIDS. 1998. PMID: 9708399 Clinical Trial.

3

Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.

Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P. Greenberg RN, et al. Antivir Ther. 2003 Feb;8(1):37-42. Antivir Ther. 2003. PMID: 12713062 Clinical Trial.

4

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P. Cardiello PG, et al. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70. doi: 10.1097/00042560-200204150-00006. J Acquir Immune Defic Syndr. 2002. PMID: 11981362 Clinical Trial.

5

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.

Schapiro JM, Winters MA, Lawrence J, Merigan TC. Schapiro JM, et al. AIDS. 1999 Feb 25;13(3):359-65. doi: 10.1097/00002030-199902250-00008. AIDS. 1999. PMID: 10199226 Clinical Trial.

6

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P. Cardiello P, et al. HIV Med. 2005 Mar;6(2):122-8. doi: 10.1111/j.1468-1293.2005.00274.x. HIV Med. 2005. PMID: 15807718 Free article. Clinical Trial.

7

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Staszewski S, et al. JAMA. 2001 Mar 7;285(9):1155-63. doi: 10.1001/jama.285.9.1155. JAMA. 2001. PMID: 11231744 Clinical Trial.

8

MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.

Katlama C, Pellegrin JL, Lacoste D, Aquilina C, Raffi F, Pialoux G, Vittecoq D, Raguin G, Lantz O, Mouroux M, Calvez V, Trylesinski A, Montestruc F, Dohin E, Goehrs JM, Delfraissy JF. Katlama C, et al. HIV Med. 2001 Jan;2(1):20-6. doi: 10.1046/j.1468-1293.2001.00046.x. HIV Med. 2001. PMID: 11737372 Free article. Clinical Trial.

9

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.

[No authors listed] [No authors listed] AIDS. 2000 Mar 10;14(4):367-74. AIDS. 2000. PMID: 10770538 Clinical Trial.

10

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M. Squires KE, et al. AIDS. 2000 Jul 28;14(11):1591-600. doi: 10.1097/00002030-200007280-00015. AIDS. 2000. PMID: 10983646 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

363 results

Results by year